Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Moodys
Citi
Farmers Insurance
Baxter
Fuji
AstraZeneca
McKesson
Covington

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,426,392

« Back to Dashboard

Which drugs does patent 8,426,392 protect, and when does it expire?

Patent 8,426,392 protects ELLA and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 8,426,392
Title:Method for providing emergency contraception
Abstract: The invention provides a method for providing emergency contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate in an oral dosage form before, during or after a meal. The invention further provides a kit comprising i) an oral dosage form comprising ulipristal acetate and ii) a printed matter stating that ulipristal acetate may be taken with or without food.
Inventor(s): Gainer; Erin (Paris, FR), Mathe; Henri Camille (Paris, FR)
Assignee: Laboratoire HRA-Pharma (Paris, FR)
Application Number:12/633,885
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,426,392
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,426,392

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cipla
Merck
Cerilliant
Baxter
Harvard Business School
Julphar
AstraZeneca
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.